ACH 2928

Drug Profile

ACH 2928

Alternative Names: ACH-2928

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Achillion Pharmaceuticals
  • Class Antivirals; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 31 Dec 2012 Discontinued - Phase-I for Hepatitis C in USA (PO)
  • 05 Dec 2011 Interim efficacy and adverse events data from a phase Ia/Ib trial in Hepatitis C (patients and volunteers) released by Achillion Pharmaceuticals
  • 11 Jul 2011 Phase-I clinical trials in Hepatitis C (in patients and volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top